Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.
Ann Oncol
; 30(11): 1821-1830, 2019 11 01.
Article
in En
| MEDLINE
| ID: mdl-31504139
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biomarkers, Tumor
/
Receptor, ErbB-2
/
Antineoplastic Agents, Immunological
/
Ado-Trastuzumab Emtansine
/
Neoplasms
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Country/Region as subject:
America do norte
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2019
Document type:
Article